When Equity Supply Looks Quiet, but Market Plumbing Isn’t
Why primary issuance, lockup releases and market plumbing matter more than the headline IPO count
When Equity Supply Looks Quiet, but Market Plumbing Isn’t
The IPO reopening is broad enough to matter, but the near-term test is not the headline deal count. It is whether new issuance, lockup releases, buybacks and trading-system capacity can coexist without turning narrow windows into sharp volatility.
The lead: a reopening with a crowded second act
The US IPO market has moved from drought toward reopening. Goldman Sachs says the market had seen just shy of 50 US IPOs by late June—about twice the pace at the same point in 2025—and roughly $120 billion of issuance, already comparable with 2021’s full-year record in dollar terms.[1] EY’s Q2 review reaches a similar conclusion from a broader angle: strong first-half activity could set up a consequential second half, but execution windows remain episodic and can be shaped by mega-IPOs and geopolitics.[2]
That does not make a new bubble the base case. Goldman’s comparison is useful: the long-run average is about 100 US IPOs per year, versus more than 250 in 2021 and almost 400 in 1999. The current recovery is large in dollars but not yet euphoric in deal count.[1]
The more important question is supply absorption. Goldman estimates that IPOs plus follow-ons could total about $700 billion in 2026, or roughly 1% of the equity market, while buybacks are expected to exceed $1 trillion.[1] That aggregate math is supportive—but it can hide timing, concentration and liquidity mismatches.
Four different flows, one market
“Equity supply” is not one event. Investors should separate the flows that change the available float from the flows that change daily trading pressure.
| Flow | What changes | Why the plumbing matters |
|---|---|---|
| IPO primary issuance | New shares and cash enter the public market | A small initial float can make price discovery fragile |
| Follow-ons and secondaries | Existing or newly issued shares are redistributed | Large blocks can compete for the same risk budget as IPOs |
| Lockup releases | Previously restricted holders may sell | The calendar can matter more than the original IPO date |
| Buybacks | Companies remove shares, often over time | Demand may offset supply in aggregate, but not necessarily on the same day or in the same names |
The market can therefore look balanced at the index level while individual stocks experience very different conditions. Goldman describes a backdrop of high individual-stock volatility and low correlations: stocks are moving sharply in different directions even when the index is comparatively stable.[1] For new listings, that is a reminder that an orderly index is not proof of orderly price discovery.
Mega-deals can be catalyst and constraint
A large, well-received IPO can validate investor appetite and encourage more issuers to proceed. It can also absorb attention, underwriting capacity and liquidity, temporarily crowding out smaller deals. EY explicitly frames anticipated mega-IPOs as both a catalyst and a constraint: strong aftermarket performance could support broader issuance, while the transactions themselves may concentrate capital and attention.[2]
The regional picture reinforces the point. EY says AI-related issuance is the dominant driver in US dollar terms, while the number of deals is more diverse across healthcare and industrials. It also identifies semiconductors, power, data-center infrastructure, robotics and advanced manufacturing as active themes across markets.[2] A thematic pipeline can deepen demand, but it can also increase correlation when investors treat several offerings as versions of the same trade.
One live example is Shein’s planned Hong Kong listing. Reuters reported on August 20 that the company was targeting a September 1 debut, while noting that the date could move; the report said the target valuation was $26 billion to $27 billion, versus a $100 billion private-market valuation in 2022, and that cornerstone investors would be subject to a six-month lockup.[3] The lesson is not a valuation judgment. It is that timing, price discovery, cornerstone demand and future float can remain linked well after the first trading day.
Lockups turn the calendar into a supply map
An IPO’s first-day float is only the opening configuration. As lockups expire, previously restricted shares may become eligible for sale, increasing the potential supply even if no new primary capital is raised. Goldman notes that many 2026 IPOs came with relatively small floats and that more shares could reach the market as lockups expire, making the outlook more challenging in 2027 and beyond.[1]
A practical checklist is more informative than a single “shares unlocked” headline:
- Eligible shares: How many shares can legally be sold, and by which holder groups?
- Actual float: How much is realistically available after strategic, insider and long-term holdings are considered?
- Trading capacity: Can average daily volume absorb even a fraction of potential selling without a wide price response?
- Information asymmetry: Are newly eligible holders more informed than the marginal buyer?
- Concurrent supply: Are follow-ons, convertibles, employee sales or other offerings arriving in the same window?
- Demand offset: Are buybacks active in the same security, or only supportive at the broad-market level?
This framework avoids a common mistake: treating the notional value of unlockable shares as if it were a guaranteed cash sale. Eligibility is potential supply, not realized supply. But potential supply can still affect positioning and volatility before a sale occurs.
Buybacks are a demand counterweight, not a perfect hedge
Buybacks complicate the simple “too much stock” narrative. Goldman expects corporate repurchases to exceed $1 trillion in 2026, more than the projected combined IPO and follow-on volume in dollar terms.[1] That is meaningful market-wide demand.
It is not a mechanical hedge for every issuance event. A company buying its own shares does not necessarily absorb a newly listed company’s shares. Repurchases may also be constrained by blackout periods, execution rules, price limits, board authorizations or a different time horizon from an IPO allocation. The correct conclusion is conditional: aggregate corporate demand can support the system, while name-level supply shocks can still produce sharp outcomes.
The disclosure regime is another piece of market plumbing. The SEC’s Rule 10b-18 safe harbor provides conditions for issuer repurchases, while 2026 exchange and listing-rule changes show that market structure is not static. In March, the SEC approved amendments to NYSE American’s initial listing standards.[4] The precise effect on issuance will depend on implementation and issuer behavior, but listing standards, quoting incentives and routing economics influence which companies reach public markets and how liquidity is supplied once they do.
What would confirm an orderly reopening?
The base case is a market that can absorb more issuance because the overall equity market is larger, corporate demand remains substantial and the number of deals is not yet at historic-euphoria levels. The risk case is more local and more mechanical: concentrated mega-deals, small floats, synchronized lockup releases and high single-stock volatility could create fragile trading conditions even while aggregate supply looks modest.
Evidence for the orderly case would include:
- New listings that maintain two-sided volume after the initial allocation period.
- Follow-ons pricing without a broad deterioration in comparable stocks.
- Lockup releases that increase turnover rather than trigger persistent one-way selling.
- Buybacks remaining active outside blackout windows.
- IPO breadth expanding beyond a narrow AI and infrastructure cluster.
Evidence for the stressed case would include repeated first-week reversals, widening spreads, falling depth, concentrated allocations and multiple supply events competing for the same investor base.
What to watch next
- The next US pricing and listing wave: IPO calendars can change quickly; treat “upcoming” dates as provisional until confirmed by issuer or exchange disclosures. A late-August calendar snapshot listed Scribe Therapeutics (SCTX) among recent 2026 US listings.[5]
- Hong Kong execution: Shein’s target date was September 1 in Reuters’ August 20 report, but the same report said the timing could slip.[3]
- Lockup schedules: Track eligibility dates, not just IPO dates, and distinguish potential from actual selling.
- Float and depth: Watch turnover, spreads and displayed depth around new listings and secondary offerings—not only closing prices.
- Buyback timing: Aggregate authorization is less useful than executed repurchases and the periods in which companies are permitted to transact.
- Exchange rules: Listing standards, market-maker incentives and routing changes can alter the economics of liquidity provision over time.
- AI concentration: If issuance remains concentrated in semiconductors, power, data centers and robotics, a shift in that theme could affect both IPO demand and the aftermarket together.[2]
The market-structure conclusion is deliberately narrower than a bull or bear call: the IPO reopening is real, but its durability will be judged by the quality and distribution of liquidity after the deal—not by the number of ribbon-cuttings on the calendar. As 2026 progresses toward the larger lockup supply of 2027 and beyond, the useful signal will be whether capital markets broaden smoothly or repeatedly force investors through the same narrow door.
This article is for research and education only and is not investment advice.